Fresenius Medical Care (NYSE:FMS) Stock Price Expected to Rise, Truist Financial Analyst Says

Fresenius Medical Care (NYSE:FMS) had its target price raised by research analysts at Truist Financial from $23.00 to $25.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Truist Financial’s price target suggests a potential upside of 10.18% from the stock’s previous close.

Several other equities research analysts also recently issued reports on FMS. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Berenberg Bank began coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price for the company. Finally, StockNews.com began coverage on shares of Fresenius Medical Care in a research report on Friday, January 3rd. They set a “strong-buy” rating on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Fresenius Medical Care has a consensus rating of “Hold” and an average target price of $25.30.

Fresenius Medical Care Price Performance

Shares of NYSE FMS opened at $22.69 on Monday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The firm’s 50-day simple moving average is $22.32 and its 200 day simple moving average is $20.71. The stock has a market cap of $13.32 billion, a price-to-earnings ratio of 18.75, a PEG ratio of 0.95 and a beta of 0.92. Fresenius Medical Care has a fifty-two week low of $17.93 and a fifty-two week high of $24.31.

Institutional Investors Weigh In On Fresenius Medical Care

A number of hedge funds have recently made changes to their positions in the business. Allworth Financial LP increased its holdings in Fresenius Medical Care by 53.1% during the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock worth $36,000 after buying an additional 581 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its stake in shares of Fresenius Medical Care by 4.5% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock worth $278,000 after purchasing an additional 624 shares during the last quarter. MML Investors Services LLC raised its holdings in shares of Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock worth $320,000 after purchasing an additional 753 shares during the period. Rhumbline Advisers lifted its stake in Fresenius Medical Care by 6.7% in the second quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock valued at $345,000 after purchasing an additional 1,128 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in Fresenius Medical Care by 8.5% during the second quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock valued at $293,000 after purchasing an additional 1,207 shares during the period. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.